Based on data from the INTERLACE Trial, induction chemotherapy (once-a-week intravenous (IV) carboplatin area under the AUC 2 and paclitaxel 80 mg/m2 for 6 weeks) followed by standard cisplatin-based chemoradiotherapy is acceptable in fit patients with stage IIB cervical cancer with granulocyte colony stimulating factor support and ability to bridge to concurrent chemoradiation within 7 days of completing induction chemotherapy [13]. The gene discussed is CSF3; the disease is cervical cancer.